Navigation Links
Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011

HARBIN, China, Oct. 4 /PRNewswire-Asia-FirstCall / -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company intends to launch three new therapeutics during the first quarter of 2011.  Weikang expects that its new products have the potential to add up to approximately $3.1 million in revenue and up to approximately $1.1 million in net income combined in 2011.  

"We are pleased to be able to regularly launch high margin new products that enable us to continue expanding our market penetration and future revenue and net income growth," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Over the past few years our research and development team have been extremely focused on developing a strong pipeline of high-quality, therapeutics to address today's important health issues. In addition, we ensure that our products are produced using the highest quality of natural ingredients and advanced processing technologies for maximum effectiveness."

The new therapeutics have been approved by the State Food and Drug Administration (SFDA).  A brief description of the new therapeutics expected to be launched in first quarter 2011 is listed below:


  • Shouwu Long Life is primarily used to strengthen kidney and cardiovascular system, as well as improve blood circulation in mature adults.  It is also beneficial in treating dizziness, ringing in the ears, forgetfulness, and early graying.

  • Lysozyme Buccal is an antibiotic tablet which can effectively treat the acute and chronic pharyngitis, upper respiratory infections and ulceration symptoms.

  • Rongrun

  • Ha Ge Jiao Lan is used to treat symptoms associated with menopause as well as increase youthful vitality and balance hormones.

  • About Weikang Bio-Technology Group Co., Inc.Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang.  For more information, please visit

    Safe Harbor StatementThis press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.Company contact:Ren Hu, VP of FinanceWeikang Bio-Technology Group Co., Inc.US Tel: (201) 887-0415China cell: 13718728163Email: rhu@weikangbio.comInvestors Relation contacts:John Marco, Partner, Elite IRTel:   +1-310-819-2948Email: John.marco@elite-ir.comLeslie J. Richardson, Partner, Elite IRTel:   +852-3183-0283Email:

    SOURCE Weikang Bio-Technology Group Co., Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
    2. Weikang Bio-Technology Announces Filing for NASDAQ Listing
    3. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
    4. Texas Health Plans Implementing Cost-Sharing From Employers to Employees by Focusing on Increasing Generic Utilization
    5. Colleen Goggins, Worldwide Chairman, Consumer Group Plans Retirement From Johnson & Johnson in Early 2011
    6. OrthoAccel Technologies Committed to Plans for Positioning the United Kingdom as a Key Strategic Market for New Orthodontic Technology
    7. Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010
    8. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
    9. UBM Announces Plans for Japan Pharma & Bio Events
    10. GeoVax Labs, Inc. Plans Public Offering
    11. As Biopharma Companies Reshape Sales Model, Most See Resetting Territory Size and Implementing Individualized Call Plans as First Steps Toward Change, According to New Research From Best Practices, LLC
    Post Your Comments:
    (Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
    (Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
    (Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
    (Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
    (Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
    (Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
    Breaking Medicine News(10 mins):